METHODS FOR TREATING HCV
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 17, 2016
app pub date -
Dec 2, 2014
filing date -
Oct 9, 2012
priority date (Note) -
Abandoned
status (Latency Note)
Importance
|
US Family Size
|
Non-US Coverage
|
Abstract
The present invention features therapies for the treatment of HCV comprising direct-acting antiviral agents. Preferably, the treatment is administered to an HCV-infected patient who has been tested to determine expression levels of microRNAs such as miR-122 or miR-21. In one aspect, the therapies comprise administering one or more direct acting antiviral agents and, optionally ribavirin, to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2, an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
First Claim
Other Claims data not available